Swoop plays a pivotal role in empowering leading pharmaceutical brands to enhance patient education regarding disease states and potential therapies while encouraging active patient involvement in their treatment journeys. Their HIPAA-certified and NAI-accredited system of engagement is designed to pinpoint unique target audiences, enabling precise activation of patient populations and their healthcare ecosystems through cross-channel marketing strategies. Incorporating artificial intelligence, machine learning, and evolutionary computation, and leveraging a real-world data universe encompassing over 300 million de-identified patients and 65 billion anonymized social determinants of health signals, Swoop's audience segments stand out for their superior quality. These segments not only optimize conversion rates but also contribute to a significant increase in Rx lift.

The Swoop System of Engagement

Precision through Machine Learning and Artificial Intelligence: Swoop leverages advanced technologies, including machine learning and artificial intelligence, to identify highly specific and privacy-safe direct-to-consumer (DTC) and healthcare professional (HCP) segments. This approach ensures a superior audience quality, allowing pharmaceutical companies to deliver more effective educational content and achieve increased script lift.

One-Size-Fits-All Approach: Traditional DTC and HCP segments created by agencies, data providers, and technology companies often lack customization to meet the unique needs and therapeutic advantages of pharmaceutical companies. This results in undifferentiated messages that broadly target a large audience, potentially missing the right targets and leading to poor conversion rates and lift.

Evolutionary Computation in Healthcare Marketing: Healthcare marketing is advancing into the era of evolutionary computation, utilizing deep learning and artificial intelligence to extract real-world insights from extensive data. Swoop embraces this standard to create precise audience segments and activation strategies tailored to pharmaceutical companies' specific requirements.

Swoop's Impact on Audience Quality, Rx Lift, and Adherence: Swoop's system of engagement excels in uncovering exclusive segments with higher Audience Quality (AQ), resulting in improved conversion rates, increased prescription volume (Rx lift), and enhanced patient lifetime value. This comprehensive approach demonstrates Swoop's commitment to driving positive outcomes for pharmaceutical companies.

Cross-Channel Activation for Enhanced ROI: Swoop's custom audiences are seamlessly activated across multiple channels, enabling pharmaceutical companies to engage the right audience at the right time with the right message. This includes programmatic, social media, connected television, linear television, on-demand audio, and more, contributing to a higher return on investment (ROI).

AI-Generated Digital Audiences: With a team comprising experienced data scientists, life sciences experts, and digital marketing professionals, Swoop introduces the industry's first HIPAA-certified and NAI-accredited system of engagement. Their use of machine learning, artificial intelligence, and evolutionary computation, combined with a vast data pool, results in exclusive audiences tailored to client-specific market definitions and performance criteria. This innovative approach outperforms traditional targeting methods, offering greater performance and effectiveness.

Swoop DTC Marketing Solutions: Empowering Patients for Informed Treatment Journeys

Swoop's DTC Marketing Solutions are designed to empower patients, encouraging them to actively participate in their treatment journeys. By leveraging Predictive AI Targeting, Swoop identifies exclusive, privacy-safe patient audiences of higher quality, ultimately driving prescription (Rx) lift. Life sciences companies have long been constrained by generic, one-size-fits-all target segments. Swoop challenges this norm by offering exclusive patient audiences tailored to a brand's specific market definition and core therapeutic advantages. This approach enables life science companies to educate patients about disease states and potential therapies, fostering active participation in their medical journeys.

Swoop's proprietary approach involves defining and uncovering exclusive audiences based on client-specific market definitions and performance criteria. This fuels cross-channel marketing strategies that engage the ideal patient with personalized messages through the most effective channels. The result is a significant improvement in performance compared to traditional targeting approaches. Swoop takes pride in being the industry's first consumer health data company to be a member of the NAI (Network Advertising Initiative) and have its own Privacy Board. This commitment to privacy ensures that patient data is handled responsibly and ethically.

As an engaged member of the NAI, Swoop assures 100% compliance with the NAI 2020 Code of Conduct Guidelines. Furthermore, Swoop's segment-building methodology is approved for both sensitive and non-sensitive conditions, showcasing its dedication to maintaining privacy standards across all healthcare contexts.

Scott Rines | President

Scott brings over 20 years of building performance-focused client development teams in health care and CPG. He previously served as Chief Revenue and Marketing Officer for Government Solutions Group as well as SVP of Business Development for Catalina Marketing.

“Through exclusive, privacy-safe audience targeting driven by Predictive AI, we elevate audience quality and drive significant Rx lift, setting a new standard in personalized healthcare engagement.”